Alamar Biosciences Launches Innovative Alzheimer's Diagnostic Assay
FREMONT, Calif. - Alamar Biosciences, Inc. (NASDAQ: ALMR), a pioneering force in precision proteomics, has made a significant stride in advancing Alzheimer's research by introducing the Research Use Only (RUO) NULISAqpcr™ AD 5-plex Assay. This groundbreaking assay allows for the simultaneous quantitative analysis of five essential blood-based biomarkers, in alignment with the Alzheimer's Association's recommended practices, facilitating improved monitoring of the disease.
Key Features of the NULISAqpcr AD 5-plex Assay
The NULISAqpcr AD 5-plex Assay represents a leap forward in Alzheimer's research, allowing for the detection of crucial biomarkers such as brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (A?42), glial fibrillary acidic protein (GFAP), and the APOE4 carrier status. Remarkably, all these measurements can be conducted from a single sample of blood or plasma, enhancing the efficiency of biomarker analysis.
How this Assay Enhances Research
By consolidating these pivotal biomarkers into one streamlined format, the NULISAqpcr AD 5-plex Assay offers unmatched sensitivity and specificity. This assay not only assists researchers in monitoring amyloid and tau pathology but also provides insights into neurodegeneration and inflammation. Moreover, it helps identify APOE4 carriers, who are at an increased genetic risk for developing Alzheimer's disease, thus broadening its clinical importance.
A Milestone in Precision Proteomics
Dr. Yuling Luo, founder and CEO of Alamar, expressed excitement over the launch, stating, "The NULISAqpcr AD 5-plex Assay marks a significant milestone. By integrating critical protein targets into one assay, we empower the neuroscience community to enhance screening, early detection, and precision diagnoses for Alzheimer's disease." This new tool underscores Alamar's commitment to providing cutting-edge solutions aimed at transforming the healthcare landscape.
The Growing Importance of Blood-Based Biomarkers
In the realm of Alzheimer's research, blood-based biomarkers are redefining conventional diagnostic methods. Dr. Steven Williams, Chief Scientific Officer at Alamar, reassured, "Blood-based biomarkers offer an accurate, cost-effective, and readily accessible way to establish early diagnoses and determine eligibility for therapeutic interventions. Traditional tests require multiple visits for separate testing, but with NULISA™, measuring multiple proteins related to the disease in blood will now deliver a comprehensive view of the patient's condition."
Collaboration for Better Outcomes
Alamar seeks to foster collaboration with researchers, clinicians, and industry partners to leverage its innovative technologies. The NULISAqpcr AD 5-plex Assay is now available as part of Alamar’s Technology Access Program, bringing its state-of-the-art solutions closer to practitioners aiming to improve patient outcomes connected to Alzheimer's and other neurodegenerative disorders.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately-held life sciences company with a mission to revolutionize the early detection of diseases through precision proteomics. Utilizing its proprietary NULISA™ technology and the ARGO™ HT System, Alamar is designed to address critical limitations in existing technologies and deliver ultra-high sensitivity in research methodologies. The potential applications of their technology extend beyond Alzheimer's, impacting broader areas in neurodegenerative research.
Frequently Asked Questions
What is the NULISAqpcr AD 5-plex Assay?
The NULISAqpcr AD 5-plex Assay is a diagnostic tool that allows the simultaneous measurement of five significant blood-based biomarkers associated with Alzheimer's disease.
Why is this assay significant for Alzheimer’s research?
This assay enhances the ability to monitor Alzheimer's symptoms more effectively by providing critical biomarker data from a single blood sample.
Which biomarkers are included in the assay?
The assay measures BD-pTau217, NfL, A?42, GFAP, and APOE4 carrier status.
Who are the key people behind Alamar Biosciences?
Dr. Yuling Luo is the founder and CEO, while Dr. Steven Williams serves as the Chief Scientific Officer.
How can researchers gain access to the NULISAqpcr AD 5-plex Assay?
Researchers can access the assay through the Technology Access Program offered by Alamar Biosciences.
